[The glutamate hypothesis of schizophrenia].
For many years, the dopamine hypothesis of schizophrenia has been the leading theory explaining the aetiology of schizophrenia. However, since the first observation showed that NMDA-receptor antagonists (e. g., PCP) can induce all kinds of schizophrenia symptoms in humans, the glutamate hypothesis of schizophrenia has been established as an additional explanation model. Apart from the PCP-induced psychoses, many other findings from all areas of modern neuroscience have confirmed and extended the glutamate hypothesis. This review discusses the available evidence for the glutamate hypothesis and puts the different findings into relation. Consecutively, the possibilities for a pharmacological modulation of the glutamate system and recent clinical trials are discussed. To sum up, one could note that the glutamate hypothesis of schizophrenia is now well-established. The development of glutamatergic antipsychotics is still in the early stages, but there is hope for a new generation of antipsychotics based on the glutamate hypothesis of schizophrenia. However, recent findings from registration trials could not provide positive findings for the recently developed glutamatergic drugs.